H uman immunodeficiency virus is the causative agent of AIDS, which currently poses one of the greatest global threats to human health. According to the World Health Organization, the population infected with HIV rose in 2004 to its highest level ever: an estimated 36 -44 million (World Health Organization, http://www.unaids.org/wad2004/report.html). This fact underscores the urgent need for an effective AIDS vaccine. Despite vigorous research efforts, preventive (sterilizing) immunization based on raising neutralizing Abs against HIV components has proved fruitless (1) (2) (3) . In contrast, it is known that the host CTL responses provide powerful defense to contain the virus postinfection (4, 5) , and CTL-based immunization is currently the most promising approach toward vaccine development (6) . At present, the most relevant animal model for investigating HIV pathology is the SIV infection of the nonhuman primate rhesus monkeys, with both the viruses and the infected hosts being genetically close (7) (8) (9) (10) . SIV and HIV have high nucleotide sequence homology, a similar tropism for CD4 ϩ T cells, and induce similar pathologies (5, 7, 9) . Moreover, immune system components of rhesus monkeys and humans are highly conserved. For example both have MHC and TCR genes that present the same regions of lentiviral Gag and Env proteins (7, (11) (12) (13) (14) . At the molecular level, it has been reported that the binding motif of the peptide to MHC class I molecules between human and rhesus monkeys is conserved in general (15) , although Mamu-A*01 shows a special preference for P3 proline as anchor residue, which is not a case for any other known human HLAs (15) . For all of these reasons, the SIV/rhesus model has been extensively explored as an invaluable tool for vaccine evaluation (16, 17) .
Among the host CTL defense system of rhesus monkey, an allele of class I MHC, Mamu-A*01, has been associated with slow progression to AIDS-like syndrome (18 -21) , and animals that expressed this allele show the best control over SIV replication (22) . Systematic studies were performed to discover its epitopes and their specific CTLs (7, 23, 24) . Two well-characterized epitopes, "TL8" from the SIV transcriptional transactivator (Tat) protein (residues 28 -35, TTPESANL; note that in some studies, the "SL8," STPESANL, sequence was used) and "CM9" from the SIV group-specific Ag (Gag) protein (residues 181-189, CTPY DINQM) have been found to be immunodominant, and CTLs specific for these two epitopes are detected in the acute stage of SIV infection (7, (25) (26) (27) . Following the initial peak expression, TL8-specific CTLs declined precipitously after the acute phase, whereas CM9-specific CTLs remained at a constant level throughout the chronic phase of infection (25, 27) . Unfortunately, these powerful host defense mechanisms also impose strong selective pressure on the evolution of the viruses (27) (28) (29) . TL8 escape variants were detectable during the very early stage of infection, whereas CM9 escape variants appeared much later (27, 30) . Eventually, the mutants will dominate the virus population and result in the progression to AIDS, as reported in both rhesus monkey and human hosts (27) . Evasion of the host immune system via CTL escape was found to be a major obstacle in CTL-based vaccine strategies (27, (31) (32) (33) .
The availability of the SIV/rhesus model makes it possible to perform systematic studies on CTL escape. A number of escape mutants of various Mamu-A*01-restricted epitopes, including CM9 and TL8, were documented (20, 26) . As a step toward delineating the molecular basis of CTL escape, we undertook structural studies to reveal how Mamu-A*01 binds these two very different SIV peptides for presentation to the TCR. Previously, several studies have probed the interactions and structures of peptide and class I MHC molecules (pMHC) 3 from human and mice (34 -38) . This is the first nonhuman primate pMHC structure ever solved, and the results show that the nonamer and octamer peptides bind to the Mamu-A*01 in a similar way with P3 as an anchor residue. The results we describe in this study provide a structural basis for T cell immune escape and have implications in the rational design of CTL-based vaccines against AIDS.
Materials and Methods

Peptide synthesis
The Gag (181-189) CTPYDINQM peptide (denoted CM9) and Tat (28 -35) TTPESANL peptide (denoted TL8) were synthesized and purified by HPLC reverse phase chromatography (SciLight Biotechnology). The purities of the peptides are Ͼ90% as assessed by HPLC (data not shown).
Crystallization and data collection
The overexpression and purification of Mamu-A*01 and ␤2-microglobulin (␤2m) and the crystallization of the Mamu-A*01/CM9 complex has been reported previously (39) . The Mamu-A*01/TL8 complex was prepared by the same procedures. Crystals of the Mamu-A*01/CM9 and Mamu-A*01/ TL8 complexes were obtained under the optimized condition (0.1 M Tris (pH 8.5), 1.8 M ammonium sulfate) in 8 wk. Data for the CM9 and TL8 crystals were collected on a Rigaku R-AXIS IVϩϩ image plate with a Rigaku MM007 rotation Cu K␣ anode home x-ray generator at 40 kV and 20 mA ( ϭ 1.5418Å). The crystals were soaked for several minutes in the reservoir solution supplemented with 20% glycerol as a cryoprotectant and then flash cooled directly in liquid nitrogen. Diffraction data collected at 100 K to 2.8 Å were processed using the program HKL2000 (40) ( Table I) . b Rmerge ϭ ͚h͚I ͉IihϪϽIhϾ͉/͚h͚I ϽIhϾ, where ϽIhϾ is the mean intensity of the observations Iih of reflection h. c R factor ϭ ͚ (͉͉Fobs͉ϪFcalc͉͉)/͚͉Fobs͉; R free is the R factor for a subset (5%) of reflections that was selected prior to refinement calculations and not included in the refinement.
d Ramachandran plots were calculated using the program PROCHECK.
Structure determination and refinement
The structures of the Mamu-A*01/CM9 and Mamu-A*01/TL8 complexes belong to the I422 space group. The structure of Mamu-A*01/CM9 was solved by molecular replacement using the HLA-B*5301 molecule (Protein Data Bank code: 1A1M; with the peptide excluded) as a search model, using the program CNS (38, 41 
Results
Overall structures of Mamu-A*01/peptide complexes
Both of the complex crystal structures contain residues 1 to 276 of the Mamu-A*01 H chain, residues 1 to 99 of human ␤2m, and SIV peptides (CM9 or TL8). The overall structure of Mamu-A*01 is similar to other class I MHC molecules, with a H chain consisting of the characteristic ␣1/␣2 and ␣3 domains, and the ␤2m chain ( Fig. 1 ). Mamu-A*01 shares significant sequence homology with other MHC molecule, including ϳ85% sequence identities among primates and 70% with mice ( Fig. 2) . We compared the structure of the Mamu-A*01/CM9 complex with representative structures of Black arrows above the alignment indicate ␤-strands; cylinders denote ␣-helices. Residues highlighted in red are absolutely conserved, whereas those highlighted in yellow are highly (Ͼ80%) conserved. Green numbers denote residues that form disulfide-bonds. The alignment was generated using the program Clustal X (56) and drawn with ESPript (57).
human and mouse origins. The root-mean-squared (r.m.s.) deviations between Mamu-A*01/CM9 and other class I MHC molecules for superposition over all C␣ atoms are below 1.6 Å. In the two complex structures reported in this study, the respective Mamu-A*01 molecules have a r.m.s. deviation of 0.58 Å for all C␣ atoms, suggesting that the two Mamu-A*01 molecules are identical within the limits of experimental error. Detailed interaction between the bound peptides and the Mamu-A*01 H chain are listed in Table II .
Conformations of the bound peptides
The electron densities for the bound peptides CM9 and TL8 are well-defined inside the peptide-binding grooves of Mamu-A*01 (Fig. 3, A and B) . The side chains of the central residues of both peptides are directed into solvent and make few contacts with residues in the ␣1 and ␣2 helical domains of the Mamu-A*01 H chain (Fig. 3, A and B) . Both peptides make extensive polar and nonpolar contacts with residues of Mamu-A*01 (Table II) .
By superimposing the binding domains of these complexes, we found that the TL8 and CM9 peptides adopt similar extended conformations with the P2, P3, and C-terminal residues in near-identical positions to serve as anchor residues to the Mamu-A*01-binding groove (Fig. 4A) . In the central region of CM9, from P4 to P6, the backbone of the peptide arches out of the binding groove.
The TL8 peptide is one residue shorter and the effects of arching of its central residues (P4 and P5) are not as pronounced as those of CM9. To accommodate an extra residue, the P4 and P5 residues of CM9 follow a small zigzag across the width of the binding groove.
The P3 anchor residue, the C-terminal residues, and P2 residue are totally buried. The P4, P5, and P8 residues of CM9 and P4, P5, and P7 residues of TL8 remain solvent accessible after binding, with relative solvent accessibilities varying from ϳ40% to 80% (Table III) .
P3 anchor residue
It has been known for some time that proline in the P3 position is an absolutely conserved feature shared by all Mamu-A*01-restricted epitopes reported to date (7, 15, 23, 24) . The two Mamu-A*01/peptide complex models provide a structural explanation for this observation. The peptide-binding groove of Mamu-A*01 contains a well-defined hydrophobic pocket (D pocket) that is optimal for binding the P3 proline side chain, constituted by the side chains of residues Tyr 9 , Arg 97 , and Tyr 159 ; and the allele-specific residues Val 99 and Met 156 (Fig. 5 ). In addition, the pyrrolidine ring of the P3 proline stacks against the aromatic ring of Tyr 159 , with a nearest distance of 2.9 Å, and offers extra stability (Fig. 5) . These data argue for a stringent stereochemical requirement for proline in position P3: a more bulky residue cannot be accommodated, whereas a smaller residue cannot form the optimal hydrophobic interactions required for binding.
In most MHC class I molecules, tyrosine in position 99 is conserved, except in H-2K b , where its counterpart is serine, which can form hydrogen bonds. However, in Mamu-A*01 and H-2D d , the residues at position 99 are valine and alanine, respectively. The side chains of valine and alanine are relatively small, which provide more space to accommodate the P3 proline side chain of the peptide. Furthermore, valine and alanine cannot form hydrogen bonds. As in H-2L d , in pocket B, position 63 is alanine, which cannot form any hydrogen bonds to P2-Pro. Thus, we postulate that it is the nonpolar residues at position 99 that ensure the P3 proline to packs in the right place complementary to the pocket (34, 38, 44, 45) . Similarly, in H-2D d , which also has an absolute preference for proline as the third residue of the epitope (34), it has alanine, another residue with a small hydrophobic side chain, at position 99. a Accessible surface areas were calculated with the program NACCESS using a solvent probe of radius 1.4 Å (http://wolf.bms.umist.ac.uk/naccess/). Relative accessibility of each residue was calculated as the percentage of accessibility compared to the accessibility of that residue in an extended Ala-Xaa-Ala tripeptide conformation (60). 143 and extends deeply into the hydrophobic pocket together with the side chain of P9-Met, which firmly anchors the C terminus of the peptide (Fig. 6A) . In contrast to CM9, the TL8 peptide binds to Mamu-A*01 with a C-terminal P8-Leu that has its side chain slightly reoriented from the CM9 P9-Met side chain (Fig.  6, A and B) .
C terminus anchor residue
Compared with the human and mouse MHC complex structures, the residues forming the F pocket of Mamu-A*01, Tyr 84 , Thr 143 , and Asp 77 are rather conserved. These residues usually form hydrogen bonds to the C-terminal residues. There are water molecule-mediated hydrogen bonds with Asp 77 and Thr 80 (Table II and Fig. 6, A and B) . The pattern of C-terminal hydrogen bonds in the Mamu-A*01/peptide complexes is very similar to those of human and mouse complexes. Like most class I MHC molecules, the F pocket of Mamu-A*01 can accept aliphatic P-omega side chains (Leu, Met, Ile, and Val) (46) .
Unique P2 residue
The B pockets of MHC class I molecules including Mamu-A*01, HLA-A*0101, and HLA-B*5801 are constituted by a conserved peptide-binding motif with Met/Thr at residue 45, Asn at residue 66, and Met at residue 67. There is a strong preference for a small residue, either threonine, serine, or alanine, in the P2 position of the peptide (15, 24) . From the two Mamu-A*01/peptide structures reported in this study, the P2-Thr residues are found to be in contact with these three residues' conserved peptide-binding motif residues (Table II) . In addition, two bulky tyrosine residues Tyr 7 and Tyr 9 on the bottom of the pocket protrude upwards and define a small volume to accommodate the P2 side chain. In both of the Mamu-A*01 complex structures, we found that the side chains of P2-Thr form hydrogen bonds with Glu 63 and Asn 66 (Fig. 6 , C and D, and Table II) . Presumably serine in position P2 can be accommodated in the way as a threonine, thus maintaining these two hydrogen bonds.
Buried P1 residue
In both complex structures, the N-terminal (P1) residue of each peptide is buried in pocket A with a reduction of Ͼ160 Å 2 in accessible surface area (Table III) . The main-chain atoms of this residue contribute to the overall binding of the peptides. Pocket A is formed by the residues Met 5 , Tyr 7 , Tyr 167 , and Tyr 171 , which are highly conserved in most class I molecules (Fig. 2) . The amino group of the P1 residue of CM9 forms hydrogen bonds with both Tyr 7 and Tyr 171 of Mamu-A*01, whereas the carbonyl group of this residue forms a hydrogen bond with Tyr 159 . The P1 residue of TL8 is able to adopt a similar conformation and interacts with these same tyrosine residues (Fig. 6, C and D) . Hydrogen bonding with the N-terminal residue of the bound epitope is a recurring theme among class I MHC molecules (24, 37) . Therefore, we conclude that the hydrogen bonding pattern of the N-terminal residue of the bound peptide, similar to the C-terminal residues, is relatively conserved.
Interactions of the middle residues in the peptide and the roles of water molecules
In CM9, the P6-Ile and P7-Glu residues show no interaction with the floor of the binding pocket (the ␤-sheet) and they are largely buried, having relative solvent accessibilities of 23 and 28%, re- spectively (Table III) . In some human pMHC complexes (of HLA-A*1101), the side chains of residues in the central P6 (of nonamer) or P7 (of decamer) positions are directed into the binding pocket and contribute significant secondary interactions to anchor the peptide (47) . With Mamu-A*01, however, the equivalent residues (P6 and P7 of CM9; P6 of TL8) adopt different conformations. Instead of pointing downwards, their side chains extend parallel to the ␤-sheet floor of the binding groove and make van der Waals interactions with the ␣1 and ␣2 helices of Mamu-A*01 (Fig. 3 and Table II ).
In the Mamu-A*01/CM9 structure, water molecule W348 mediates four important hydrogen bonds between the Mamu-A*01 residues Glu 70 and Arg 97 and the CM9 residue P7-Gln within the C and E pockets (Table II and Fig. 6A ). In the Mamu-A*01/TL8 complex, water molecules W24 form three hydrogen bonds between the TL8 residue P8-Leu, and the Mamu-A*01 residues Asn 77 and Thr 80 within the F pocket (Table II and Fig. 6B ). The locations of the two water molecules are not conserved between the two structures.
Discussion
The structures reported in this study provide detailed information regarding peptide presentation by the rhesus monkey Mamu-A*01, an important MHC allele that has been used in many systematic investigations into SIV infection. These are the first-ever solved nonhuman primate pMHC complex structures and allow many published functional data to be interpreted from a structural perspective. Apart from AIDS, nonhuman primate models are invaluable in studying other human diseases, such as rheumatoid arthritis, hepatitis, malaria, etc. (15) .
SIV epitopes bind to Mamu-A*01 with a two-point anchorage resembling the motif of binding by several known human and mouse class I MHC molecules, including HLA-A*01, HLA-B*08, and H-2D b (7, 24) . Similar to other pMHC complex structures, the SIV epitopes have the characteristic P2 and C-terminal anchor residues in the peptide-binding motif. The unique structural feature of the Mamu-A*01-restricted epitope is an absolute requirement for proline in the P3 position as one of its major anchor residues (23). Precedents for P3 anchors have been reported in the context of both the murine (H-2D d ) and human (HLA-A*01 and -B*08) MHC molecules (7, 24) . Interestingly, the murine structure also has a P3-Pro anchor that is stabilized by the ring stacking with MHC residue Tyr 159 (34) . In addition to interactions between protein and peptide atoms, water molecules have been shown to be important in bridging hydrogen bonds in almost every MHC peptide structure determined to date, including the two structures we solved in this study (48) . Our structural observations provide two examples of water molecules contributing additional hydrogen bonds and fine-tuning the binding interface between a MHC molecule and its epitopes.
It is interesting to compare the structure of the CM9 (CTPY DINQM) peptide reported in this study here with that of a highly similar HIV-2 epitope (TPYDINQML, TL9) that is part of the complex with HLA-B*53 (38) . The HIV-2 epitope is identical in sequence to SIV Gag 182-190 (i.e., CM9 shifted by one residue to the C-terminal), such that CM9 and TL9 are related by a singleresidue offset relative to each other. Despite having eight of their nine residues in common, the two nonamers have totally different conformations when induced to fit into optimal binding to their respective MHC molecules (Fig. 4B) . Therefore, it cannot be inferred that epitopes with similar sequences bind to MHC molecules with similar peptide conformations. In a previous study, it was found that HIV-2-derived TL9 binds 25-fold weaker than CM9 to Mamu-A*01 (7).
Similarly, another interesting epitope that is highly related to CM9 is Gag CL10 (CTPYDINQML), which is essentially CM9 plus one extra residue at the C terminus. CL10 is restricted by a distinctly different CTL clone (7), but it binds to Mamu-A*01 with a similar affinity to CM9 (7) . The bound conformation of the CL10 epitope may result in a different C-terminal anchorage from CM9.
For the CM9 peptide, residues P4-Tyr, P5-Asp, and P8-Gln show the highest degree of solvent exposure (Table III) and are the best candidates for TCR binding. For TL8, residues P4-Glu, P5-Ser, and P7-Asn also display a high degree of solvent exposure. In the crystal structures of HLA-A*1101 complexed with two HIV epitopes, the side chains of the P4, P5, P7, and P8 residues (for the nonamer peptide), or the P4, P5, P8, and P9 residues (for the decamer peptide) have the highest solvent exposure and are proposed as the best candidates for TCR recognition (47) . We examined previous work on natural and artificial mutations of SIV/HIV to gain insights into the TCR binding site on the Mamu-A*01/ peptide structures. It has been shown that alanine substitutions in either the P7 or P8 positions of a HLA-A*11-restricted peptide eliminate TCR recognition without affecting the binding affinity, whereas substitutions at P4 and P5 have no effect (47, 49) . These results for the human MHC class I homologue are in striking contrast to those of Mamu-A*01. A recombinant SIV that has an alanine substitution at the CM9 P8-Gln residue (Gag Q188A; also known as "Q53A") behaves very much like the wild-type virus and stimulates CM9-specific CTL responses (50) . This argues against P8-Gln of CM9 playing a role in TCR binding. In contrast, a naturally occurring P5-Ser to leucine (Tat S32L) variant is resistant to CTL lysis while its binding to Mamu-A*01 is not lost, suggesting that this residue is important in TCR recognition (26) . Taken together, residues in the P4 and P5 positions are the more likely determinants for TCR binding, whereas the involvement of residues at the C terminus are debatable. It is noteworthy that the work on HLA-A11 was performed using a CTL clone, whereas the work on Mamu-A*01 was conducted using a cell line. Therefore, it should be possible to isolate a CTL clone from this cell line that recognizes the P8-residue. Studies using these specific conditions should be performed in the future to address these issues.
MHC class I molecules bind the dimeric CD8␣␣ coreceptor mainly via its ␣3 domain (51, 52) . It can be inferred that the CD8 binding site of Mamu-A*01 is also located on this surface because the ␣3 domain of Mamu-A*01 is highly conserved (Figs. 1 and 2) .
The SIV/rhesus monkey model has contributed significantly to our current understanding of the effects of CTL escape. The evasion of CTL responses can occur at two levels: either the mutated epitope does not bind to the MHC molecule, or the pMHC complex is no longer recognized by the TCR. The two Mamu-A*01-restricted epitopes we used in this study have been extensively studied and their escape variants have been characterized. CTL escape variants of CM9 are rare and they arise at a later stage of infection, consistent with CM9 being derived from a structurally and/or functionally constrained part of Gag where mutations cannot be tolerated (28) . Most consistently, the T182I variant (P2 location of the epitope; or "T47I" in some studies) is the only one that turned up in several investigations (20, 31, 53) . According to a previous study, the T182I mutation of CM9 leads to decrease in binding to Mamu-A*01 by two orders of magnitude (24, 31) . We studied the Mamu-A*01/CIPYDINQM complex and observed a dramatically reduced complex yield in refolding experiments (F. Chu, G. F. Gao, unpublished results), suggesting a significantly reduced binding affinity. From the Mamu-A*01/CM9 structure, pocket B is simply not large enough to accommodate the isoleucine side chain that is just slightly bigger. Furthermore, the two hydrogen bonds contributed by P2-Thr are lost as a result of mutation.
In contrast, escape variants of TL8 restricted by Mamu-A*01 are diversified and they appear very early postinfection, implying that this part of the Tat protein is nonessential and can tolerate mutations without compromising survival (26, 27, 30) . Although the most dramatic loss in binding to Mamu-A*01 was caused by mutations in the P2 and P8 anchor positions, CTL escape can be achieved by mutations in any of the eight residues (26) . In this study, we discuss the structural consequences of several predominant mutations, namely, T28P (P1 residue, also known as "S28P" in some studies), T29I (P2), S32L (P5), L35Q, L35P, and P35R (P8 residue) (26, 30) . The Tat T29I mutation is analogous to the Gag T182I mutation at the P2 location, resulting in a side chain that is unable to fit in the B pocket, as discussed above. From the Mamu-A*01/TL8 structure, the P8-Leu residue is an important residue that is completely buried in the F pocket (Table III) , which has a strong preference for hydrophobic residues in the C-terminal anchor position (24) . Replacement of P8-Leu with either proline, arginine, or glutamine would result in a loss of this optimal Cterminal anchorage due to the mutant side chain being too bulky, or sterically unfit, or due to burial of polar or charged atoms. The T28P (P1 position) and S32L (P5 position) mutants are 2-and 7-fold weaker in binding, respectively. As revealed by the Mamu-A*01/TL8 structure, the P1 and P5 residues do not contribute significantly to the stability of the complex. Presumably, these two mutations would compromise the shape complementarity at the protein-peptide interface but will not abolish binding. It is more likely that these two mutants escape CTL via evasion of TCR recognition.
The two SIV epitopes used in this study could represent two very different strategies for viral control: TL8-specific CTLs are stimulated by very low concentration of the epitope (high "functional avidity") and are therefore promising in initial containment of acute infection (29) , whereas the CM9-specific CTLs may force the virus to escape with a severely compromised fitness and the weakened viruses may subsequently be controlled by secondary measures (27) . The two structures reported are most relevant in providing a detailed molecular understanding of the specific CTL escape, one of the major obstacles in current AIDS vaccine research. From the electron density for TL8, we observe a relatively flat peptide in the middle of the epitope, and position P5 is occupied by serine with a short side chain. In CM9, its counterpart is isoleucine in position P6. As reported by Price et al. (54) , TCR CDR3 usages for many TL8 epitope-restricted CTL clones used arginine in the middle of the CDR3. This arginine has been shown, in a HLA-A2-restricted TCR recognition, to insert into a notch formed on the Ag surface between the largely flat peptide and the MHC class I ␣2 helix (55) . This pattern of recognition of TL8 may limit the flexibility of Ag recognition and facilitates viral escape. The T cell response is mainly stimulated by the interaction of the epitope with the CDR3, but different immunodominant epitopes induce different responses. Based on this, a vaccine with a spectrum of different peptide epitopes, including the future mutant variants, would offer a stronger immune response. This strategy should be tested for the TL8 and its escape mutant S5L immunization in the rhesus model. Furthermore, the structures reported in this study also pave the way for rational vaccine design, e.g., by virtual screening in silico.
